Surrey Heartlands

Joint Formulary & PAD

Rizatriptan - Migraine (acute)

You are here : Home > Formulary Search > Rizatriptan - Migraine (acute)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Preferred
 

Status 2

Green (see narrative)
Formulations :
  • Oro-dispersible
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
R
Restrictions / Comments :
Important
Prescribe as generic orodispersible tablets (NOT oral lyophilisates). For use in patients with swallowing difficulties, nausea or vomitting.
 

Status 3

Non Formulary
Formulations :
  • Oral lyophilisates
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :
Important
Prescribe as orodispersible tablets

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Rizatriptan
Indication :
Migraine (acute)
Group Name :
Keywords :
Triptans, acute migraine, migraine treatment
Brand Names Include :
Important Information :
Prescribe generically
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Rizatriptan is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Migraine (acute).

Committee Recommendations (2)

02 Mar 16 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

UPDATED: The PCN recommends that sumatriptan, zolmitriptan, rizatriptan and naratriptan should be considered as first line triptans where clinically appropriate and should be prescribed generically.

Zolmitriptan/ Rizatriptan orodispersible tablets should be considered as a suitable first line treatment for patients when there are difficulties in swallowing the solid dose formulations or the patient has difficulties with nausea and vomiting.

02 Mar 16 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Rizatriptan oral lyophilisates (Maxalt Melt) should not be prescribed. Please see the policy statement below for further information